Arvinas Doses First Patient in Phase 1/2 Trial of ARV-6723 for Solid Tumors

07:38 AM EDT, 09/28/2026 (MT Newswires) -- Arvinas (ARVN) has dosed the first participant in a phase 1/2 clinical trial of ARV-6723 in patients with advanced solid tumors, the company said Monday. The global study will evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of orally administered ARV-6723 as a monotherapy or in combination with pembrolizumab. The first-in-human trial will initially assess the safety of ARV-6723 as a monotherapy treatment and subsequently in combination with an anti-PD-1 therapy. It will also evaluate whether deep and sustained HPK1 degradation leads to "meaningful antitumor" effects in patients, the company said.